Menlo Park, Calif. and Dallas, Texas – March 9, 2022 – ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) LNP delivery platform, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil, chief executive officer of ReCode Therapeutics will present a corporate overview at the upcoming Oppenheimer 32nd Annual Healthcare Conference being held virtually from March 15-16, 2022.

Presentation details:
Date: Wednesday, March 16, 2022
Time: 4:00 – 4:30 p.m. ET

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit and follow us on Twitter @ReCodeTx and LinkedIn.


Will Zasadny
Canale Communications, Inc.
[email protected]
(619) 961-8848

Sarah McCabe
Stern Investor Relations
[email protected]
[email protected]